Argenx Stops Phase 3 Vyvgart Trial in Sjögren’s Disease After Monitors Find the Study Cannot Meet Its Goal

Argenx ended its Phase 3 UNITY trial of efgartigimod in Sjögren’s disease after a futility review. No new safety signals were found.

Have A Referral?